Lack of association between serum syndecan-4, myocardial fibrosis and ventricular dysfunction in subjects with chronic Chagas disease.

Autor: Larocca TF; Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, IGM-Fiocruz/BA, Salvador, Bahia, Brazil., Macêdo CT; Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil.; Department of Cardiology, São Rafael Hospital, Salvador, Bahia, Brazil., Noya-Rabelo M; Department of Cardiology, São Rafael Hospital, Salvador, Bahia, Brazil., Lemos Correia LC; Department of Cardiology, São Rafael Hospital, Salvador, Bahia, Brazil.; Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil., Moreira MI; Department of Cardiology, São Rafael Hospital, Salvador, Bahia, Brazil., Caldas AC; Department of Cardiology, São Rafael Hospital, Salvador, Bahia, Brazil., Torreão JA; Department of Cardiology, São Rafael Hospital, Salvador, Bahia, Brazil., Souza BSF; Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, IGM-Fiocruz/BA, Salvador, Bahia, Brazil., Vasconcelos JF; Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, IGM-Fiocruz/BA, Salvador, Bahia, Brazil., Carvalho da Silva AS; Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil., Ribeiro Dos Santos R; Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil., Soares MBP; Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, IGM-Fiocruz/BA, Salvador, Bahia, Brazil.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2017 Dec 12; Vol. 12 (12), pp. e0189408. Date of Electronic Publication: 2017 Dec 12 (Print Publication: 2017).
DOI: 10.1371/journal.pone.0189408
Abstrakt: Background: Syndecan-4 is a transmembrane glycoprotein associated with inflammation and fibrosis. Increased syndecan-4 levels were previously detected after acute myocardial infarction and in subjects with heart failure. However, the levels of syndecan-4 in subjects with Chagas disease have not so far been investigated. The aim of this study was to investigate the potential role of serum sydencan-4 as a novel biomarker for myocardial fibrosis and cardiac dysfunction in subjects with Chagas disease.
Methods: This study comprised subjects with Chagas disease (n = 56), being 14 (25%) with the indeterminate form, 16 (29%) with the cardiac form without ventricular dysfunction, and 26 (46%) with the cardiac form with ventricular dysfunction.
Results: Syndecan-4 serum concentrations did not correlate with presence or absence of myocardial fibrosis (P = 0.386) nor disease severity in subjects with Chagas disease (P = 0.918). Additionally, no correlation was found either between the degree of myocardial fibrosis and serum syndecan-4 [r = 0.08; P = 0.567] or between left ventricular ejection fraction and syndecan-4 [r = 0.02; P = 0.864]. In contrast, NT-proBNP levels correlated with ejection fraction and myocardial fibrosis.
Conclusions: Our results demonstrate the lack of correlations between serum syndecan-4, myocardial fibrosis and cardiac dysfunction in subjects with Chagas disease. Further studies are required to show if syndecan-4 concentrations can be marker for prognosis assessment or disease progression.
Databáze: MEDLINE
Externí odkaz: